Silence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN - Free Report) in a research report sent to investors on Friday morning, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. Chardan Capital reissued a buy rating and set a $55.00 price target on shares of Silence Therapeutics in a research report on Friday, August 16th. Morgan Stanley raised their target price on Silence Therapeutics from $45.00 to $49.00 and gave the stock an overweight rating in a research note on Friday, June 28th.

Silence Therapeutics Trading Up 1.8 %

NASDAQ:SLN traded up $0.34 during trading hours on Friday, hitting $19.09. 79,571 shares of the stock were exchanged, compared to its average volume of 212,224. The firm's fifty day moving average price is $18.74 and its 200 day moving average price is $21.04. Silence Therapeutics has a 52-week low of $6.15 and a 52-week high of $27.72. The company has a market cap of $571.33 million, a P/E ratio of -16.16 and a beta of 1.30.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $11.28 million. Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. Equities analysts expect that Silence Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors have recently modified their holdings of the company. Vivo Capital LLC acquired a new position in shares of Silence Therapeutics in the fourth quarter valued at approximately $8,862,000. Parkman Healthcare Partners LLC boosted its stake in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company's stock valued at $4,046,000 after buying an additional 40,063 shares during the period. SG Americas Securities LLC grew its position in shares of Silence Therapeutics by 10.5% during the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company's stock worth $151,000 after buying an additional 667 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics during the first quarter worth approximately $43,798,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Silence Therapeutics during the first quarter worth approximately $13,575,000. 98.73% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.